Opinion|Videos|January 15, 2025
Multidisciplinary Care of EGFR-Mutant Advanced NSCLC: A Patient Perspective
Panelists discuss Melinda's perspective on care coordination during her treatment, including the healthcare professionals involved, such as those providing wound care and integrative medicine, and how their collaborative efforts supported her care, ultimately enhancing her treatment experience and confidence in her overall care.
Advertisement
Video content above is prompted by the following:
- What did coordination of care look like from your perspective during your treatment?
- Which healthcare professionals did you meet with, and how were their efforts coordinated to support your care (e.g., wound care, integrative medicine)?
- How did this team-based approach impact your treatment experience and overall confidence in your care?
Advertisement
Related to this article
In a prospective cohort, a 3-gene blood model predicted 1-year castration resistance with an AUC of 0.89 in metastatic hormone-sensitive prostate cancer.
Rutika Mehta, MD, MPH, explains how she sequences MSI, HER2, claudin 18.2, and PD-L1 testing when tissue is limited in gastroesophageal cancer.
Dirk Schadendorf, MD, outlineed which patients with BRAF V600–mutant melanoma, including those with brain metastases, may be candidates for triplet therapy.
Dirk Schadendorf, MD, discussed final STARBOARD data with encorafenib, binimetinib, and pembrolizumab and its role in BRAF V600–mutant melanoma care.
Heath Skinner, MD, PhD, discussed the 3 considerations that determine which new radiation oncology service lines his network chooses to build.
Dwight H. Owen, MBBCh, MS, discussed why severe immune-related toxicities remain hard to predict as immunotherapy combinations expand in lung cancer.
Mingjia Li, MD, discussed the limitations of current biomarkers in selecting patients with resectable NSCLC for neoadjuvant chemoimmunotherapy.
Heath Skinner, MD, PhD, discussed which new radiation oncology service lines community practices can implement, how leadership decides, and what launches require.
Advertisement
Advertisement
Trending on CancerNetwork
1
Predicting Severe Immune-Related Toxicities in Lung Cancer Immunotherapy
2
Blood mRNA Model Predicts Castration Resistance in Metastatic Prostate Cancer
3
CD19 CAR T Cell Therapy for Treatment-Refractory Seropositive Rheumatoid Arthritis: A Phase 1 Trial
4
Outpatient Treatment-Related Toxicity After Hospital Discharge Among Patients Receiving Lifileucel for Advanced Melanoma
5